Abrégé

The present application provides novel iminosugars and their use as glucosidase inhibitors. The present inventors have discovered that certain deoxynojirimycin derivatives may be effective in inhibiting glucosidases. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition where inhibiting glucosidase may be important.

Classes IPC  ?

• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles

Abrégé

The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide in the composition. The present disclosure also provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering an immunologically effective amount of the vaccine composition described herein. The present disclosure further provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering a dose of about 20 μg to about 300 μg of an HA-ss-np in a vaccine composition, wherein the vaccine composition further comprises an aluminum hydroxide; CpG ODN; and a phosphate salt, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide. Also provided herein is a method of producing a vaccine composition, comprising combining HA-ss-np with an adjuvant mixture, wherein the adjuvant mixture comprises a diluent solution comprising a phosphate salt; aluminum hydroxide; and CpG ODN, wherein the adjuvant mixture comprises CpG ODN-adsorbed aluminum hydroxide, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 47/02 - Composés inorganiques
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 37/04 - Immunostimulants

Abrégé

The present disclosure relates to influenza hemagglutinin (HA) polypeptides. In some embodiments, the disclosure provides a polypeptide comprising an amino acid sequence with at least 90% sequence identity to any one of SEQ ID NOs:31-33.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• C07K 14/11 - Orthomyxoviridae, p. ex. virus de l'influenza

Abrégé

Microsphere formulations comprising nalmefene are provided. In one aspect, the microsphere formulations are characterized in that the nalmefene is released over a period of about 60 days or more. Methods for making and using the microsphere formulations are also provided.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine

Abrégé

This disclosure is directed to N-substituted valiolamine compounds, their use as glycosidase inhibitors, and in methods of treating diseases or conditions in which glycosidase inhibition provides benefit.

Classes IPC  ?

• C07D 239/26 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles comportant au moins trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
• A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
• A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• C07C 215/44 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes amino ou des groupes hydroxy liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné liés à des atomes de carbone du même cycle ou du même système cyclique condensé
• C07C 217/08 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe hydroxy éthérifié et un seul groupe amino liés au squelette carboné, qui n'est pas substitué par ailleurs l'atome d'oxygène du groupe hydroxy éthérifié étant lié de plus à un atome de carbone acyclique
• C07C 229/10 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons
• C07C 247/16 - Composés contenant des groupes azido avec des groupes azido liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné
• C07C 271/20 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des atomes d'azote ne faisant pas partie de groupes nitro ou nitroso
• C07D 249/06 - Triazoles-1, 2, 3Triazoles-1, 2, 3 hydrogénés avec des radicaux aryle liés directement aux atomes du cycle
• C07D 257/04 - Cycles à cinq chaînons

Abrégé

Described herein are novel compositions comprising a virus or viral vector that may express viral glycoproteins, and methods of treatment using the same.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine

Abrégé

This disclosure describes a composition comprising an alkyl nitrite, such as isoamyl nitrite, and an effective amount of at least one stabilizing compound, such as one or more of vitamins K1, K2, and K3.

Classes IPC  ?

• A61K 31/21 - Esters, p. ex. nitroglycérine, sélénocyanates
• A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline

Produits et services

(1) Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing for others and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals. (2) Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Organization.

Produits et services

Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing for others and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals. Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Organization.

Abrégé

An autoinjector for administering medications. The autoinjector includes an injector unit that includes a cartridge housing, a first carpule to contain a medication for administration and a second carpule to contain a second medication. The carpules are positioned within the interior area of the cartridge housing. The autoinjector further includes an activator unit having an activation housing, a first and second activation engine positioned within an interior area of the activation housing. Each activation engine includes a spring and a piston, such that the spring and piston are co-axial with the carpules. The autoinjector further includes a retainer to retain the springs, a safety disk positioned at a proximal end of the activation housing, and a safety element to engage the safety disk and maintain the activator unit in a storage setting.

Classes IPC  ?

• A61M 5/24 - Seringues à ampoules, c.-à-d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p. ex. automatiques
• A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
• A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles

Produits et services

Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing for others and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Organization

Produits et services

Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing for others and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Organization

Abrégé

The present disclosure relates to pharmaceutical compositions comprising an opioid antagonist, isotonicity agent, a preservative agent, a stabilizing agent and citric acid. The pharmaceutical compositions are stable under various storage conditions. Methods of using the pharmaceutical compositions are also disclosed including methods of treatment

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 47/02 - Composés inorganiques
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique

Abrégé

The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide in the composition. The present disclosure also provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering an immunologically effective amount of the vaccine composition described herein. The present disclosure further provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering a dose of about 20 μg to about 300 μg of an HA-ss-np in a vaccine composition, wherein the vaccine composition further comprises an aluminum hydroxide; CpG ODN; and a phosphate salt, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide. Also provided herein is a method of producing a vaccine composition, comprising combining HA-ss-np with an adjuvant mixture, wherein the adjuvant mixture comprises a diluent solution comprising a phosphate salt; aluminum hydroxide; and CpG ODN, wherein the adjuvant mixture comprises CpG ODN-adsorbed aluminum hydroxide, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

Microsphere formulations comprising nalmefene are provided. In one aspect, the microsphere formulations are characterized in that the nalmefene is released over a period of about 60 days or more. Methods for making and using the microsphere formulations are also provided.

Classes IPC  ?

• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 36/81 - Solanaceae (famille de la pomme de terre), p. ex. tabac, Solanum ptycanthum, tomate, belladone, poivron ou datura
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

This disclosure is directed to N-substituted valiolamine compounds, their use as glycosidase inhibitors, and in methods of treating diseases or conditions in which glycosidase inhibition provides benefit.

Classes IPC  ?

• C07H 15/224 - Cycles cyclohexane substitués par au moins deux atomes d'azote avec uniquement un radical saccharide directement lié aux cycles cyclohexane, p. ex. destomycine, fortimicine, néamine
• C07H 15/00 - Composés contenant des radicaux hydrocarbonés ou hydrocarbonés substitués, liés directement aux hétéro-atomes des radicaux saccharide
• C12P 19/00 - Préparation de composés contenant des radicaux saccharide

Abrégé

The present disclosure is directed to modified coronavirus (e.g., SARS-CoV-2) spike polypeptides, nanoparticles comprising the same, methods of using the same, e.g., to generate coronavirus (e.g., SARS-CoV-2) neutralizing antibodies or antigen-binding fragments thereof. The disclosure also provides methods of using neutralizing antibodies or antigen-binding fragments thereof obtained by such methods (e.g., equine antibodies or antigen-binding fragments thereof) to treat or prevent coronavirus (e.g., SARS-CoV-2) infections in a subject.

Classes IPC  ?

• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
• C07K 19/00 - Peptides hybrides

Abrégé

This disclosure describes a composition comprising an alkyl nitrite, such as isoamyl nitrite, and an effective amount of at least one stabilizing compound, such as one or more of vitamins K1, K2, and K3.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles

Abrégé

An autoinjector for administering medications. The autoinjector includes an injector unit that includes a cartridge housing, a first carpule to contain a medication for administration and a second carpule to contain a second medication. The carpules are positioned within the interior area of the cartridge housing. The autoinjector further includes an activator unit having an activation housing, a first and second activation engine positioned within an interior area of the activation housing. Each activation engine includes a spring and a piston, such\ that the spring and piston are co-axial with the carpules. The autoinjector further includes a retainer to retain the springs, a safety disk positioned at a proximal end of the activation housing, and a safety element to engage the safety disk and maintain the activator unit in a storage setting.

Classes IPC  ?

• A61M 5/19 - Seringues avec plusieurs compartiments
• A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
• A61M 5/24 - Seringues à ampoules, c.-à-d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p. ex. automatiques

Produits et services

(1) Pharmaceutical preparations for the treatment and prophylaxis of biological infection, exposure, and contamination; pharmaceutical preparations for the treatment and prophylaxis of chemical, radiological and nuclear exposure and contamination; pharmaceutical preparations for the treatment and prophylaxis of infectious diseases; pharmaceutical products for use in biodefense (2) Medical devices for neutralizing chemical agents and toxins; injection device for pharmaceuticals (1) Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing and lyophilization, namely, freeze drying services for others, in the field of pharmaceuticals (2) Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Operation

Produits et services

Pharmaceutical preparations for the treatment and prophylaxis of biological infection, exposure, and contamination; pharmaceutical preparations for the treatment and prophylaxis of chemical, radiological and nuclear exposure and contamination; pharmaceutical preparations for the treatment and prophylaxis of infectious diseases; pharmaceutical products for use in biodefense. Medical devices for neutralizing chemical agents and toxins; injection device for pharmaceuticals. Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing and lyophilization, namely, freeze drying services for others, in the field of pharmaceuticals. Research and development in the pharmaceutical, biotechnology, and biodefense fields; research and development of pharmaceutical preparations and medicines as a contract development manufacturing operation.

Produits et services

Pharmaceutical preparations for the treatment and prophylaxis of biological infection, exposure, and contamination; pharmaceutical preparations for the treatment and prophylaxis of chemical, radiological and nuclear exposure and contamination; pharmaceutical preparations for the treatment and prophylaxis of infectious diseases; pharmaceutical products for use in biodefense. Medical devices for neutralizing chemical agents and toxins; injection device for pharmaceuticals. Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing and lyophilization, namely, freeze drying services for others, in the field of pharmaceuticals. Research and development in the pharmaceutical, biotechnology, and biodefense fields; research and development of pharmaceutical preparations and medicines as a contract development manufacturing operation.

Produits et services

(1) Pharmaceutical preparations for the treatment and prophylaxis of biological infection, exposure, and contamination; pharmaceutical preparations for the treatment and prophylaxis of chemical, radiological and nuclear exposure and contamination; pharmaceutical preparations for the treatment and prophylaxis of infectious diseases; pharmaceutical products for use in biodefense (2) Medical devices for neutralizing chemical agents and toxins; injection device for pharmaceuticals (1) Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing and lyophilization, namely, freeze drying services for others, in the field of pharmaceuticals (2) Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Operation

Abrégé

The present application provides novel iminosugars and their use as glucosidase inhibitors. The present inventors have discovered that certain deoxynojirimycin derivatives may be effective in inhibiting glucosidases. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition where inhibiting glucosidase may be important.

Classes IPC  ?

• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61P 31/12 - Antiviraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present disclosure relates to pharmaceutical compositions comprising an opioid antagonist, isotonicity agent, a preservative agent, a stabilizing agent and citric acid. The pharmaceutical compositions are stable under various storage conditions. Methods of using the pharmaceutical compositions are also disclosed including methods of treatment

Classes IPC  ?

• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées

Produits et services

Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing for others and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals Pharmaceutical preparations for the treatment and prophylaxis of biological infection, exposure, and contamination; pharmaceutical preparations for the treatment and prophylaxis of chemical, radiological and nuclear exposure and contamination; pharmaceutical preparations for the treatment and prophylaxis of infectious diseases; pharmaceutical products for use in biodefense, namely, pharmaceutical preparations to protect people against the effects of biological agents or bioterrorism Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Operation

Produits et services

Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing for others and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals Pharmaceutical preparations for the treatment and prophylaxis of biological infection, exposure, and contamination; pharmaceutical preparations for the treatment and prophylaxis of chemical, radiological and nuclear exposure and contamination; pharmaceutical preparations for the treatment and prophylaxis of infectious diseases; pharmaceutical products for use in biodefense, namely, pharmaceutical preparations to protect people against the effects of biological agents or bioterrorism Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Operation

Produits et services

DOWNLOADABLE DIGITAL MARKETING MATERIAL, NAMELY, DOWNLOADABLE ELECTRONIC PUBLICATIONS IN THE NATURE OF BROCHURES, BOOKLETS, INFORMATIONAL CARDS, AND NEWSLETTERS IN THE FIELDS OF RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL, BIOTECHNOLOGY, AND BIODEFENSE FIELDS, CONTRACT DEVELOPMENT MANUFACTURING OPERATIONS, WORLDWIDE DISEASES, MEDICAL CONDITIONS, VACCINATIONS AND TREATMENTS. PRINTED MATTER, NAMELY, BROCHURES, BOOKLETS, NEWSLETTERS AND INFORMATIONAL CARDS IN THE FIELDS OF RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL, BIOTECHNOLOGY, AND BIODEFENSE FIELDS, CONTRACT DEVELOPMENT MANUFACTURING OPERATIONS, WORLDWIDE DISEASES, MEDICAL CONDITIONS, VACCINATIONS AND TREATMENTS. RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL, BIOTECHNOLOGY, AND BIODEFENSE FIELDS; RESEARCH AND DEVELOPMENT OF PHARMACEUTICAL PREPARATIONS AND MEDICINES AS A CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATION.

Produits et services

Downloadable digital marketing material, namely, downloadable electronic publications in the nature of brochures, booklets, informational cards, and newsletters in the fields of research and development in the pharmaceutical, biotechnology, and biodefense fields, contract development manufacturing operations, worldwide diseases, medical conditions, vaccinations and treatments. Printed matter, namely, brochures, booklets, newsletters and informational cards in the fields of research and development in the pharmaceutical, biotechnology, and biodefense fields, contract development manufacturing operations, worldwide diseases, medical conditions, vaccinations and treatments.

Produits et services

pharmaceutical and veterinary preparations for diseases and conditions associated with exposure to B. anthracis organisms or spores and anthrax vaccines

Produits et services

Pharmaceutical preparations for the treatment and prophylaxis of biological infection, exposure, and contamination; pharmaceutical preparations for the treatment and prophylaxis of chemical, radiological and nuclear exposure and contamination; pharmaceutical preparations for the treatment and prophylaxis of infectious diseases; pharmaceutical products for use in biodefense Research and development in the pharmaceutical, biotechnology, and biodefense fields; Research and development of pharmaceutical preparations and medicines as a Contract Development Manufacturing Operation

Abrégé

Disclosed herein are compounds of Formula I 2, X, and Y are defined herein. These compounds are type II topoisomerase inhibitors and can be used in methods for treating infections caused by gram-positive pathogens, gram-negative pathogens, and drug-resistant strains thereof.

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
• C07D 455/02 - Composés hétérocycliques contenant des systèmes cycliques quinolizine, p. ex. alcaloïdes de l'émétine, protoberbérineDérivés alkylènedioxy des dibenzo [a, g] quinolizines, p. ex. berbérine contenant des systèmes cycliques quinolizine sans autre condensation
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles

Abrégé

Formula IA, and their use for treating viral infections.

Classes IPC  ?

• A61K 31/45 - Pipéridines non condensées, p. ex. pipérocaïne ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cycloheximide
• C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
• C07D 487/04 - Systèmes condensés en ortho
• C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 405/10 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

This disclosure provides methods for treating or preventing a disease or condition caused by or associated with a Zika virus infection in a subject. The methods can comprise administering to a subject in need thereof an effective amount of an iminosugar compound as described herein.

Classes IPC  ?

• A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques

Abrégé

This disclosure provides methods for treating or preventing a disease or condition caused by or associated with an Influenza virus or Dengue virus in a subject in need thereof. The methods can comprise administering to the subject in a first single administration step a first dose of N-(9-methoxynonyl)deoxynojirimycin or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein the first dose can range, for example, from at least 1.1 grams to about 10 grams.

Classes IPC  ?

• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• C07D 211/40 - Atomes d'oxygène

Abrégé

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens. The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

Classes IPC  ?

• A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
• A61K 38/12 - Peptides cycliques
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• C07D 455/02 - Composés hétérocycliques contenant des systèmes cycliques quinolizine, p. ex. alcaloïdes de l'émétine, protoberbérineDérivés alkylènedioxy des dibenzo [a, g] quinolizines, p. ex. berbérine contenant des systèmes cycliques quinolizine sans autre condensation

Abrégé

Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 39/07 - Bacillus
• A61K 39/12 - Antigènes viraux
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present application provide novel iminosugars and their use in treatment of viral infections, such as Dengue infection and Influenza A infection. The present inventors discovered certain deoxynojirimycin derivatives may be effective against one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition caused by or associated with one or more viruses. In certain embodiments, the deoxynojirimycin derivatives may increase a survival rate or probability for a subject infected with one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus.

Classes IPC  ?

• C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
• C07D 211/40 - Atomes d'oxygène

Abrégé

The present disclosure relates to protein molecules that specifically bind to receptor tyrosine kinase-like orphan receptor 1 (ROR1), which may have at least one humanized ROR1-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to ROR1 may have a second binding domain that binds to another target. In one embodiment, multispecific polypeptide molecules bind both ROR1-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the ROR1-binding poypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

Formula IA, and their use for treating viral infections.

Classes IPC  ?

• C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61P 31/12 - Antiviraux

Abrégé

This disclosure provides a cell-based assay for testing the potency of multispecific binding molecules which specifically bind a T-cell antigen and a target antigen for redirected T-cell-mediated cellular cytotoxicity. The assay uses the TALL-104 T-cell line as effector cells, and provides a sensitive, specific, and reproducible method for ensuring that purity, activity, and stability of multispecific binding molecule batches can be measured for development, clinical trials, and commercial marketing.

Classes IPC  ?

• C12P 21/08 - Anticorps monoclonaux
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C12N 5/07 - Cellules animales ou tissus animaux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation

Produits et services

contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals

Abrégé

The present invention provides methods of treating a patient with a B-cell malignancy or disorder comprising administering an anti-CD37 antibody or antibody fragment in combination with an anti-CD20 antibody or antibody fragment. In one embodiment, the invention provides methods for B-cell reduction comprising contacting B-cells with an anti-CD37 antibody or antibody fragment and an anti-CD20 antibody or antibody fragment. The invention includes compositions and kits comprising anti-CD37 antibody and antibody fragments for use in combination with an anti-CD20 antibody or antibody fragment. The methods and compositions of the invention may further include a BCR antagonist such as a SYK inhibitor, a BTK inhibitor, a PI3K inhibitor, or a CXCR4 antagonist.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.

Classes IPC  ?

• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present application provide novel iminosugars and their use in treatment of viral infections, such as Dengue infection and Influenza A infection. The present inventors discovered certain deoxynojirimycin derivatives may be effective against one or more viruses, which may be. for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition caused by or associated with one or more viruses. In certain embodiments, the deoxynojirimycin derivatives may increase a survival rate or probability for a subject infected with one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus.

Classes IPC  ?

• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne

Abrégé

Recombinant multispecific antibodies that bind CD3 with specificity and CD37 with specificity are disclosed. The multispecific antibodies induce target-dependent T cell cytotoxicity, activation and proliferation. Methods of treating a patient with a B-cell malignancy or disorder comprising administering to the patient compositions.comprising recombinant multispecific antibodies that bind CD3 and CD37 with specificity are further provided.

Classes IPC  ?

• C12P 21/08 - Anticorps monoclonaux
• C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide

Abrégé

Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin B. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.

Classes IPC  ?

• A61K 39/40 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire bactériens
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C12P 21/08 - Anticorps monoclonaux

Abrégé

Formulations of vaccine antigen, such as anthrax protective antigen, are provided that are stable after undergoing freeze and thaw conditions. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.

Classes IPC  ?

• A61K 9/18 - Adsorbats

Abrégé

The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with CD3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment, a multi-specific polypeptide binds both a T-cell receptor complex on T-cells and a tumor antigen to induce target-dependent T-cell cytotoxicity, activation and proliferation.

Classes IPC  ?

• C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats

Produits et services

(1) Pharmaceutical preparations for the treatment and prophylaxis of infections, of exposure to harmful organisms, noxious matter, of contamination with harmful organisms, noxious matter, namely, antibiotics, vaccines and immunotherapeutic agents; pharmaceutical preparations for the treatment and prophylaxis of chemical, radiological and nuclear exposure and contamination, namely, antibiotics, vaccines and immunotherapeutic agents; pharmaceutical preparations for the treatment and prophylaxis of cancer and autoimmune system diseases and disorders; medical devices for neutralizing chemical agents and toxins on the skin. (1) Research and development in the pharmaceutical and biotechnology fields.

Produits et services

Pharmaceutical preparations, including pharmaceutical preparations for the treatment and prophylaxis of: biological infection, exposure, and contamination; chemical, radiological and nuclear exposure and contamination; infectious diseases; and cancer and immune system diseases and disorders. Medical devices for neutralizing chemical agents and toxins. Research and development in the pharmaceutical and biotechnology fields.

Abrégé

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

Classes IPC  ?

• A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
• A61K 38/12 - Peptides cycliques
• C07D 455/02 - Composés hétérocycliques contenant des systèmes cycliques quinolizine, p. ex. alcaloïdes de l'émétine, protoberbérineDérivés alkylènedioxy des dibenzo [a, g] quinolizines, p. ex. berbérine contenant des systèmes cycliques quinolizine sans autre condensation
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles

Abrégé

Described are a series of 2-pyridone compounds as a potent and selective new class of type II topoisomerase inhibitors with broad-spectrum antimicrobial activity having the general formula (I); where R1, R2, X, and Y are defined herein Such compounds can be used in methods for treating an infection caused by a gram-positive pathogen, a gram-negative pathogen, or a drug-resistant strains thereof.

Classes IPC  ?

• C07D 455/02 - Composés hétérocycliques contenant des systèmes cycliques quinolizine, p. ex. alcaloïdes de l'émétine, protoberbérineDérivés alkylènedioxy des dibenzo [a, g] quinolizines, p. ex. berbérine contenant des systèmes cycliques quinolizine sans autre condensation
• A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine

Abrégé

The present invention relates generally to fusion proteins comprising anti-sIL6xR binding domains and methods of using same. Such proteins are useful, for example, in methods for treating any of a variety of inflammatory disorders including rheumatoid arthritis, psoriasis and ulcerative colitis.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Produits et services

Pharmaceutical preparations for the treatment and prophylaxis of: biological infection, exposure, and contamination; chemical, radiological and nuclear exposure and contamination; infectious diseases; and cancer and immune system diseases and disorders Medical devices for neutralizing chemical agents and toxins Research and development in the pharmaceutical and biotechnology fields

Abrégé

The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.

Classes IPC  ?

• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 infuenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against anthrax infection.

Classes IPC  ?

• A61K 39/07 - Bacillus

Abrégé

The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). One chain of a heterodimer comprises a binding domain that specifically binds a target (e.g., a receptor). In addition, both chains of a heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in reducing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.

Classes IPC  ?

• C07K 16/46 - Immunoglobulines hybrides
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

This disclosure provides immunoglobulin binding molecules that specifically bind to human macrophage stimulating receptor (MST1 R, also referred to herein as recepteur d'origine Nantaise or RON), including antibodies and monospecific and multispecific single chain binding proteins having one or more other domains, such as one or more antibody constant region domains. Also provided are therapeutic applications of such binding proteins, such as for the treatment of cancer and inflammatory disorders.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.

Classes IPC  ?

• C07K 16/46 - Immunoglobulines hybrides
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present disclosure relates to compositions and methods for treating autoimmune diseases including rheumatoid arthritis. In particular, the present disclosure relates to compositions comprising IL-6 antagonists (e.g., anti-IL6 or anti-IL6R or anti-hyperIL6) and TNF-Alpha antagonists (e.g., (anti-TNF or etanercept) and methods of using same in the treatment of rheumatoid arthritis.

Classes IPC  ?

• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 17/06 - Antipsoriasiques
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention provides vaccine compositions useful in prevention and treatment of Chlamydia sp. {e.g., C. trachomatis or C. pneumoniae) infection. Provided are polypeptide vaccine antigens comprising Chlamydia HtrA-derived sequences, including epitopic fragments, analogs, derivatives, and variants. Also provided are methods for inducing an immune response to a subject against Chlamydia infection, for preventing Chlamydia infection, or for treating a disease or symptom caused by or resulting from infection with Chlamydia, for instance, C. trachomatis or C. pneumoniae. In one embodiment, the present invention is drawn to C. trachomatis HtrA, which induces a cellular immune response and imparts partial protective immunity in vivo.

Classes IPC  ?

• A61K 39/02 - Antigènes bactériens

Abrégé

The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phosphatidylinositol 3-kinase (PI3K) inhibitors (such as p110?-specific inhibitors or the like), which can be done concurrently or sequentially, to treat or prevent a B cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine

Abrégé

Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against anthrax infection.

Classes IPC  ?

• A61K 39/07 - Bacillus
• A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif

Abrégé

The present invention provides an export signal system based on E. coli CS3 antigen for directing the secretion of foreign antigens from host cells. In particular, the invention describes genetic constructs encoding fusion proteins that contain a CS3 export signal fused to at least one heterologous amino acid sequence. Attenuated microorganisms expressing the fusion proteins and pharmaceutical compositions comprising such attenuated microorganisms are also disclosed.

Classes IPC  ?

• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci

Abrégé

Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCRα, TCRβ, or CD3ε, along with compositions and methods of use thereof are provided.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Attenuated microorganisms expressing Clostridium difficile antιgen(s), and methods of using the same for vaccination of patients are disclosed The invention provides an attenuated microorganism expressing an immunogenic portion of a C difficile Toxin A C-terminal repeat region and/or a C difficile Toxin B C-terminal repeat region The microorganism is an attenuated Salmonella comprising an integrated gene expression cassette that directs the expression of the immunogenic peptide from an in vivo inducible promoter.

Classes IPC  ?

• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/36 - Adaptation ou atténuation de cellules

Abrégé

This disclosure provides a multi-specific fusion protein composed of a CD72-ligand binding domain and another binding domain specific for a heterologous target, such as a B-cell specific protein. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The present invention provides recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of Chlamydia sp. (e.g., C. trachomatis or C. pneumoniae) infection. Provided is rMVA comprising polynucleotides encoding Clamydia antigens, including epitopic fragments, analogs, derivatives, and variants. Also provided are methods for inducing an immune response to a subject against Chlamydia infection, for preventing Chlamydia infection, or for treating a disease or symptom caused by or resulting from infection with Chlamydia, for instance, C. trachomatis or C. pneumoniae.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 39/12 - Antigènes viraux
• A61K 39/275 - Poxviridae, p. ex. Avipoxvirus

Abrégé

This disclosure provides a multi-target fusion protein composed of a TGF? antagonist domain and another binding domain antagonistic for a heterologous target (such as IL6, IL10, VEGF, TNF, HGF, TWEAK, IGF) or agonistic for a heterologous target (such as GITR). The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

A binding domain polypeptide and fusion proteins thereof that recognize an IL6/IL6 receptor complex, as well as compositions and methods of use thereof.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/46 - Immunoglobulines hybrides

Abrégé

This disclosure provides a multi-target fusion protein composed of a TNF-α antagonist domain and another binding domain antagonistic for a heterologous target, such as IL6, RANKL, IL7, IL17A/F, TWEAK, CSF2, IGF1, IGF2 or BLyS/APRIL, or agonistic for a heterologous target, such as IL10. The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Classes IPC  ?

• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG promoter. In one embodiment of the invention, the immunogenic Chlamydial peptide is a PmpG peptide, for instance, a CT110, CT84 or CT40 peptide.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/255 - Salmonella (G)

Abrégé

A method is provided for the production of soluble Clostridium neurotoxins or neurotoxin fragments, for instance, LHN fragments from botulinum neurotoxins. Proteins made according to the method of the invention are useful, for example, as immunodiagnostic agents and vaccine components.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

A method of synthesizing stereochemically defined iminocyclitol comprises replacing an intraring oxygen in a cyclic sugar by an intraring imine to form an iminocyclitol, wherein said iminocyclitol has a defined stereochemical configuration different from a stereochemical configuration of the cyclic sugar. The invention also provides combinatorial libraries of iminocyclitol compounds, allowing for diverse C1 and N-substitution. In addition, provided are methods of treating viral infections with iminocyclitols compounds.

Classes IPC  ?

• C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
• C07H 5/04 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure à l'azote
• C07H 5/06 - Sucres aminés

Abrégé

The invention provides compositions comprising an antigenic botulinum neurotoxin serotype E (BoNT/E) peptide, wherein the peptide has improved solubility and thus improved ability to stimulate an immune response against BoNT/E holotoxin. The composition may be used as part of a multivalent vaccine regimen via coordinated use with non-serotype E BoNT peptides, such as one or more BoNT/A and/ or BoNT/B peptides. It further provides processes for manufacturing said BoNT/E peptide. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a BoNT/E and optionally one or more non-serotype E BoNT peptides such as one or more BoNT/A and/ or BoNT/B peptides.

Classes IPC  ?

• A61K 39/08 - Clostridium, p. ex. Clostridium tetani

Abrégé

The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a Chlamydia infection. The present invention is also directed toward an isolated nucleic acid encoding a polypeptide comprising at least 70% identity to any one of SEQ ID NOS: 2, 11, 13, 19, or 21, wherein the polypeptide is soluble in the absence of denaturing agents. In some aspects of the invention, the polynucleotide is codon-optimized. In some embodiments, the present invention is related to the polypeptide encoded by the polynucleotide of the invention. Administration of polypeptides of the present invention can be used as a method to treat or prevent a Chlamydia infection in an animal in need thereof.

Classes IPC  ?

• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07K 1/00 - Procédés généraux de préparation de peptides

Abrégé

The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated with a chemical modifying agent to improve its ability to stimulate an immune response. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a vaccine.

Classes IPC  ?

• A61K 39/02 - Antigènes bactériens
• A61K 39/07 - Bacillus
• A61K 39/08 - Clostridium, p. ex. Clostridium tetani

Abrégé

The present invention provides vaccine compositions useful in prevention and treatment of Chlamydia sp. {e.g., C. trachomatis or C. pneumoniae) infection. Provided are polypeptide vaccine antigens comprising Chlamydia HtrA-derived sequences, including epitopic fragments, analogs, derivatives, and variants. Also provided are a method for inducing an immune response to a subject against Chlamydia infection, a method for preventing Chlamydia infection, or a method for treating a disease or symptom caused by or resulting from infection with Chlamydia, for instance, C. trachomatis or C. pneumoniae. In one embodiment, the present invention is drawn to C. trachomatis HtrA, which induces a cellular immune response and imparts partial protective immunity in vivo.

Classes IPC  ?

• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• C07K 1/00 - Procédés généraux de préparation de peptides
• A61K 39/118 - Chlamydiaceae, p. ex. Chlamydia trachomatis ou Chlamydia psittaci

Abrégé

The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a Group B Streptococcus (GBS) infection. The present invention is also directed toward a composition comprising two or more of polypeptides, wherein said polypeptide comprises an amino acid sequence at least 80% identical to the reference amino acid sequence selected from the group consisting of Pho1-13, Pho1-14, Pho1-5, Pho3-3 (pho1-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3- 29, Pho3-50, MS4, MS11, MS16, MS14, MS10(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, a fragment, variant, analog, or derivative thereof, wherein said polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence. In some embodiments, the present invention is directed to a method of inducing an immune response in a host comprising administering to said host an effective amount of the composition of the present invention.

Classes IPC  ?

• A61K 39/09 - Streptococcus
• A61K 39/40 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire bactériens
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Produits et services

(1) Pharmaceutical preparations, namely, anthrax vaccine.

Produits et services

Smallpox vaccines.

Produits et services

(1) Smallpox vaccines.

Produits et services

smallpox vaccines

Produits et services

(1) Pharmaceutical preparations, namely vaccines, immunotherapeutics and biologics for prophylactic and therapeutic purposes for the treatment of infectious diseases and disorders caused by chemical, biological, radiological and nuclear contamination and immune system diseases and disorders, namely autoimmune diseases, immunologic deficiency syndromes; and anti-infectives. (1) Scientific research services in the biodefense field; scientific research in the field of health and medicine; biologics development services; medical testing services for prophylactic and therapeutic purposes; medical testing services for prophylactic and therapeutic purposes; medical research services.

Produits et services

Pharmaceutical preparations, namely, vaccines, immunotherapeutics and biologics, immunobiotics for prophylactic therapeutic purposes. Scientific research services; biologics development services; medical research services. Medical testing services for prophylactic and therapeutic purposes; medical services.

Produits et services

Pharmaceutical preparations, namely, vaccines and biologics for prophylactic therapeutic purposes for the treatment of infectious diseases and disorders related to infectious diseases

Produits et services

(1) Pharmaceutical preparations, namely vaccines, immunotherapeutics, biologics and immunobiotics for prophylactic therapeutic purposes, all for the treatment of infectious diseases and disorders related to infectious diseases. (1) Scientific research services; biologics development services; medical research services, all related to the biodefense field. (2) Medical testing services for prophylactic and therapeutic purposes; medical services, all related to the biodefense field.

Produits et services

Pharmaceutical preparations, namely vaccines, immunotherapeutics and biologics, immunobiotics for prophylactic therapeutic purposes. Scientific research services; biologics development services. Medical testing services for prophylactic and therapeutic purposes; medical research services; medical services.

Produits et services

Pharmaceutical preparations, namely anthrax vaccines.

Produits et services

Pharmaceutical preparations, namely, vaccines, immunotherapeutics, biologics, and immunobiotics for prophylactic therapeutic purposes for the treatment of infectious diseases and disorders related to infectious diseases

Produits et services

Printed publications, namely, a series of articles and reviews, and brochures regarding the pharmaceutical, medical, biodefense, biochemical, and biological fields [ Education and training, namely, providing seminars and workshops in the pharmaceutical, medical, biodefense, biochemical, and biological fields; arranging and conducting conferences, conventions, and seminars in the pharmaceutical, medical, biodefense, biochemical, and biological fields ]